Eris Lifesciences · NSE: ERIS · BSE: 540596
Q2 FY19 results · Jul–Sep 2018
Eris Lifesciences reported revenue from operations of ₹264.18 crore and net profit of ₹85.51 crore for Q2 FY19 (Jul–Sep 2018), on a consolidated basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 264.18 | — | — | 250.76 | +5.4% |
| Other income | 6.15 | — | — | 3.52 | +74.6% |
| Total income | 270.34 | — | — | 254.28 | +6.3% |
| Profit before tax | 92.31 | — | — | 77.69 | +18.8% |
| Net profit for the period | 85.51 | — | — | 71.56 | +19.5% |
| Attributable to shareholders of the company | 85.32 | — | — | 71.25 | +19.7% |
| EPS, basic (₹) | 6.20 | — | — | 5.18 | +19.7% |
| Net margin (%) | 32.4 | — | 28.5 |
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 240.81 | — | — | 226.50 | +6.3% |
| Other income | 6.24 | — | — | 4.51 | +38.5% |
| Total income | 247.05 | — | — | 231.00 | +6.9% |
| Profit before tax | 89.99 | — | — | 75.42 | +19.3% |
| Net profit for the period | 83.98 | — | — | 70.10 | +19.8% |
| EPS, basic (₹) | 6.10 | — | — | 5.10 | +19.6% |
| Net margin (%) | 34.9 | — | 31.0 |
Consolidated
- Filed with BSE
- 06 Nov 2018, 15:12 IST
- Board meeting
- 03 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2018, 15:12 IST
- Board meeting
- 03 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE